TARTAN LLC

SAN DIEGO, CA · Founded 2021 · CIK 0001866378 · Biotech · Private

RNA editing therapy for SCN1A mutations in Dravet syndrome using cell-type-specific targeting

tartan.com →
Grants
$256K
1 award
Sector median: 1
Raised
$130K
1 Form D · Aug 2021
62 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: Harnessing the power of introns for safe and effective therapeutics and genomic screening$255,730
Private capital raisedForm D · SEC$130,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2650SIDERO BIOSCIENCE, LLC—$145K
2651ORION THERAPEUTICS INC.—$145K
2652Finch Therapeutics, Inc.—$4.5M
2653TARTAN LLC—$130K
2654NEUIMMUNE, INC.—$125K
2655RESTORE THERAPEUTICS LLC——
2656nVector, Inc.—$125K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Christopher DoyleDirector · Executive Officer · Promoter
  • Sage RatermanDirector · Executive Officer · Promoter

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.